drugset / Trial / NCT00896493

Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

NCT00896493

Phase 2 Completed 38 enrolled Stanford University
NaSingle-groupOpen-labelTreatment

Summary

Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given that the median age at diagnosis is 55-60 years and frequently present compromised skin in these patients, which increases the risk of infection. Therefore, we propose a clinical study with allogeneic hematopoietic stem cell transplantation (HSCT) using a unique non-myeloablative preparative regimen, TLI/ATG, to treat advanced mycosis fungoides/Sezary syndrome (MF/SS).

Timeline

Start
2009-05
Primary completion
2021-11-06
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Background ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic 1.5 mg/kg Intravenous
Background Cyclosporine Peptide 5 mg/kg Oral